Fernandina Beach, FL – March 10, 2025 – GalenusRx, a leader in innovative medication safety assessment and management solutions, welcomes Pierantonio Russo, MD, FCPP, mACP, mSTS, FAAP, to its Advisory Board. Dr. Russo brings experience in cardiac and heart transplant surgery and executive expertise in data and analytics, health economics and reimbursement, health insurance and population medicine.
Dr. Russo holds a Certificate in Health Care Innovation-Health and Health Care Administration Management from the University of Pennsylvania-Philadelphia and a Certificate in Digital Medicine (Node. Health). He is a member of the STS, FAAP, and FCPP and a professional member of the AHA. Currently, he is the Corporate Chief Medical Officer at Eversana (www.eversana.com) and is on the advisory board of several health services organizations.
He has held numerous clinical and administrative leadership positions, including Chief of Cardiac Surgery, Pediatric Cardiac Surgery and Heart Transplantation, at several Academic Hospitals in the USA and was fellow in heart transplantation and circulatory mechanical support at the Texas Heart Institute, Houston, TX. Additionally, Dr. Russo brings 27 years of academic experience in both full-time and adjunct roles. He’s served in full-time academic positions in surgery and pediatrics at Temple Medical School, Thomas Jefferson Medical College, the Allegheny University (PA) and the University of Missouri (MO). He was adjunct professor of Biotechnology at Temple University, Philadelphia, taught for the Wharton School of Business (International program), and was on the Harvard Medical School Faculty as Lecturer in Population Medicine. Dr Russo has been Medical Director at Independence Blue Cross (Philadelphia) and VP Medical and Clinical Affairs at Harvard Pilgrim (Boston).
“We are delighted to welcome Dr. Pierantonio Russo to the GalenusRx advisory board,” said Calvin H. Knowlton, PhD, Co-CEO and Executive Chairman, GalenusRx. “His extensive expertise and innovative vision will be invaluable as we continue to advance our mission of improving medication safety and patient outcomes. Pierantonio’s insights will undoubtedly help us drive forward our initiatives and make a lasting impact on the healthcare and pharmaceutical industry.”
Dr. Russo also shared excitement regarding his appointment, stating, “I am thrilled to join the GalenusRx advisory board. This opportunity allows me to contribute to a groundbreaking platform. By leveraging advanced analytics and providing pharmaceutical companies with tools to forecast adverse drug events virtually without any risk of patient harm, GalenusRx is poised to make a significant impact on the pharmaceutical industry.”
GalenusRx’s proprietary platform, APPRAISE™, provides comprehensive risk assessments by analyzing drug-drug, multi-drug, drug-gene, and drug-disease interactions. This innovative approach ensures that patients receive the safest and most effective medication regimens tailored to the unique characteristics of each patient, including genetic make-up. GalenusRx creates personalized treatment plans resulting in better outcomes including total medical cost savings.
